Exact Sciences Q4 Earnings Match Estimates, Revenues Beat, Stock Up

Core Insights - Exact Sciences Corporation (EXAS) reported a net loss of 21 cents per share in Q4 2025, which is higher than the loss of 6 cents in the same quarter last year, aligning with the Zacks Consensus Estimate [1] - For the full year 2025, earnings per share were 7 cents, a significant improvement from the loss of 23 cents in the previous year [1] EXAS Revenues - Q4 consolidated revenues reached $878.4 million, reflecting a 23.1% increase on a reported basis and 23% on a core revenue basis, surpassing the Zacks Consensus Estimate by 2.1% [2] - Full-year 2025 consolidated revenues totaled $3.25 billion, marking a 17.7% increase on a reported basis and 18% on a core revenue basis [2] - Following the earnings announcement, EXAS shares saw a slight increase of 0.07% [2] EXAS Q4 Segments in Detail - Screening revenues, which include laboratory service revenues from Cologuard and PreventionGenetics, amounted to $695.1 million, up 26% year over year [3] - Precision Oncology revenues, including laboratory service revenues from global Oncotype products and therapy selection products, were $183.2 million, reflecting a 14% year-over-year increase and 12% on a core basis [3] EXAS' Margins - Gross profit increased by 25% year over year to $615.8 million, with gross margin expanding by 106 basis points to 70.1% [4] - Research and development expenses rose by 96% year over year to $191.5 million, while sales and marketing expenses increased by 18% to $288.5 million [4] - General and administrative expenses grew by 14.1% year over year to $218 million [4] EXAS' Financial Update - At the end of Q4 2025, Exact Sciences had cash and cash equivalents and marketable securities totaling $964.7 million, down from $1.04 billion at the end of Q4 2024 [6] - Cumulative net cash provided by operating activities was $491.4 million, compared to $210.5 million in the previous year [6] Notable Developments - In Q4, Exact Sciences announced the first clinical study results from its Oncodetect molecular residual disease test in breast cancer, which showed favorable outcomes [10] - The company also reported pivotal clinical validation results from the ALTUS study during the quarter [10] - On November 19, 2025, Exact Sciences entered into a merger agreement with Abbott Laboratories, aiming for a close in Q2 2026, pending regulatory approvals [11]